	US 11,717,561 B2
	Multimodal antimicrobial therapy
Gerald W. Fischer, Bethesda, MD (US); and Richard F. Schuman, Boyds, MD (US)
Assigned to Longhorn Vaccines and Diagnostics, LLC, Bethesda, MD (US)
Filed by Longhorn Vaccines and Diagnostics, LLC, Bethesda, MD (US)
Filed on Oct. 26, 2017, as Appl. No. 15/794,157.
Application 15/794,157 is a continuation of application No. 14/584,110, filed on Dec. 29, 2014, granted, now 9,814,766, issued on Nov. 14, 2017.
Claims priority of provisional application 61/921,442, filed on Dec. 28, 2013.
Prior Publication US 2018/0042999 A1, Feb. 15, 2018
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/48 (2006.01); A61P 31/06 (2006.01); A61P 31/08 (2006.01); A61L 29/16 (2006.01); A61K 45/06 (2006.01); A61K 9/00 (2006.01); A61P 31/00 (2006.01); A61K 9/16 (2006.01); A61K 9/50 (2006.01); A61L 31/16 (2006.01); C12N 9/64 (2006.01)

CPC A61K 38/4886 (2013.01) [A61K 9/0073 (2013.01); A61K 9/16 (2013.01); A61K 9/50 (2013.01); A61K 45/06 (2013.01); A61L 29/16 (2013.01); A61L 31/16 (2013.01); A61P 31/00 (2018.01); A61P 31/06 (2018.01); C12N 9/6489 (2013.01); A61L 2300/254 (2013.01); A61L 2300/404 (2013.01); A61L 2300/45 (2013.01); C12Y 304/24075 (2013.01); Y02A 50/30 (2018.01)]

13 Claims

1. A pharmaceutical composition comprising:

a recombinantly engineered enzyme that is a glycyl-glycine endopeptidase;

an anti-Mycobacterial compound that is effective against a Mycobacteria which acts synergistically with the glycyl-glycine endopeptidase, wherein the anti-Mycobacterial compound is selected from the group consisting of cycloserine, isoniazid, and ethambutol; and

antibodies against Mycobacteria; and

wherein the composition is encapsulated and the encapsulated composition is biodegradable and provides a slow-release or a timed-release of enzyme when administered to a patient.